Philadelphia, PA, United States of America

Joshua Joyner Sims

USPTO Granted Patents = 1 

Average Co-Inventor Count = 5.0

ph-index = 1


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Joshua Joyner Sims in Gene Therapy

Introduction

Joshua Joyner Sims is an accomplished inventor based in Philadelphia, PA. He has made significant contributions to the field of gene therapy, particularly through his work on adeno-associated virus (AAV) vectors. His innovative approaches have the potential to advance therapeutic applications in various medical fields.

Latest Patents

Sims holds a patent for "Adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor." This patent describes a recombinant adeno-associated virus (rAAV) vector that comprises an AAV capsid with a heterogeneous population of vp1, vp2, and vp3 proteins. The capsid is engineered to contain modified amino acids compared to the encoded VP1 amino acid sequence, featuring highly deamidated asparagine residues at asparagine-glycine pairs, along with multiple other, less deamidated asparagine and optionally glutamine residues. This innovation aims to enhance the efficacy and safety of gene delivery systems.

Career Highlights

Throughout his career, Joshua Joyner Sims has focused on developing advanced gene therapy techniques. His work has been instrumental in improving the design and functionality of viral vectors used in therapeutic applications. His research has garnered attention for its potential to address various genetic disorders.

Collaborations

Sims has collaborated with notable researchers in the field, including James M Wilson and April Tepe. These partnerships have contributed to the advancement of his research and the development of innovative solutions in gene therapy.

Conclusion

Joshua Joyner Sims is a pioneering inventor whose work on AAV vectors represents a significant advancement in gene therapy. His contributions have the potential to transform treatment options for patients with genetic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…